The topline results found that the TenNor rifasutenizol trial showed better safety and tolerability than the current standard ...

Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) ...

The failure of the Eyenovia CHAPERONE study has seen the company’s stock value drop drastically as it weighs up options and ...

GlobalData forecasts that the prostate cancer market is set to increase by 25% from $475.84 million in 2024 to $596.22 ...

Atrial flutter is a type of abnormal heart rhythm that causes rapid and irregular beating of the upper chambers of the heart. Credit: Rawpixel.com via Shutterstock. Intellia Therapeutics has announced ...

The trial evaluated nucresiran’s safety, pharmacokinetics and pharmacodynamics in healthy individuals. Credit: Andrei_R/Shutterstock. Alnylam Pharmaceuticals has revealed new interim data from its ...

The study involved 731 participants who were randomised to receive either tirzepatide or placebo. Credit: Africa Studio/Shutterstock. Eli Lilly has reported comprehensive outcomes from the Phase III ...

AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...

The two-day Oncology event will see industry experts from across the clinical trial space holding talks on subjects from AI ...

GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...

This research will inform the final design of the Exact Sciences Cancerguard test. Credit: Studio Romantic via Shutterstock. Exact Sciences has unveiled new findings from a case-control study ...

Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe.